HLAVNÍ TÉMA Přínosy a rizika nových antidiabetik pro léčbu geriatrických pacientů s diabetem | 437 / Vnitř Lék. 2024;70(7):430-437 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz 27. Bilal A, Yi F, Gonzalez GR, et al. Effects of newer anti-hyperglycemic agents on cardiovascular outcomes in older adults: Systematic review and meta-analysis. J Diabetes Complications. 2024 Aug;38(8):108783. 28. Ledesma G, Umpierrez GE, Morley JE, et al. Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial. Diabetes Obes Metab. 2019 Nov;21(11):2465-2473. 29. Doucet J, Chacra A, Maheux P, et al. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin. 2011 Apr;27(4):863-9. 30. Karyekar CS, Ravichandran S, Allen E, et al. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging. 2013;8:419-30. 31. Iqbal N, Allen E, Öhman P. Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥ 65 years) with type 2 diabetes. Clin Interv Aging. 2014 Sep 4;9:1479-87. 32. Pratley RE, Rosenstock J, Pi-Sunyer FX, Banerji MA, Schweizer A, Couturier A, Dejager S. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care. 2007 Dec;30(12):3017-22. 33. Round EM, Engel SS, Golm GT, et al. Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs Aging. 2014 Mar;31(3):203-14. 34. Barnett AH, Huisman H, Jones R, et al. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Oct 26;382(9902):1413-23. 35. Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab. 2013 Oct;15(10):906-14. 36. Nagao M, Sasaki J, Sugihara H, et al. STREAM Study Investigators. Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study. Sci Rep. 2023 Jan 4;13(1):134. 37. Wang Y, Shao X, Liu Z. Efficacy and safety of sodium-glucose co-transporter 2 inhibitors in the elderly versus non-elderly patients with type 2 diabetes mellitus: a meta-analysis. Endocr J. 2022 Jun 28;69(6):669-679. 38. Pratley R, Dagogo-Jack S, Charbonnel B, et al. Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies. Diabetes Obes Metab. 2020 Dec;22(12):2276-2286 39. Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013 Apr;41(2):72-84. 40. Sinclair AJ, Bode B, Harris S, et al. Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis. J Am Geriatr Soc. 2016 Mar;64(3):543-52. 41. Aldafas R, Crabtree T, Alkharaiji M, et al. Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis. Age Ageing. 2024 Jan 2;53(1):afad254. 42. Pasqualotto E, Rodrigues FR, E Silva Ribeiro GB, et al. The effect of sodium-glucose transporter 2 inhibitors on stroke in patients with type 2 diabetes: A meta-analysis. J Stroke Cerebrovasc Dis. 2024 Aug;33(8):107730. 43. Pan SY, Su EL, Huang CJ, et al. Evaluation of glucose-lowering medications in older people: a comprehensive systematic review and network meta-analysis of randomized controlled trials. Age Ageing. 2024 Aug 6;53(8):afae175. 44. Kvapil M, Břízová L, Nováková M. Léčba diabetu u starších pacientů. Farmakoter Revue 2023;8(1):1–5. 45. Kvapil M, Nováková M. Antidiabetika v ordinaci internisty. Acta medicinae. 2022;14:in press. 46. Nováková M, Kvapil M. Kardiovaskulární bezpečnost antidiabetik u seniorů. Svět prakt. medicíny. 2022;4:34-35. 6. 7. 3. 2025 OLOMOUC 20. interní medicína pro praxi PŘIPRAVOVANÉ TEMATICKÉ BLOKY: Komplikace imunoterapie u onkologického pacienta Racionální ATB terapie Alergologie Case Based Learning Blok ambulantních internistů Kardiovaskulární onemocnění Perspektivy medicíny MÍSTO KONÁNÍ: CLARION CONGRESS HOTEL OLOMOUC Jeremenkova 36 Průběžně aktualizovaný program a registrace: www.kongresinterna.cz
RkJQdWJsaXNoZXIy NDA4Mjc=